Literature DB >> 579392

Cardiovascular effects of tricyclic and tetracyclic antidepressants.

D Burckhardt, E Raeder, V Müller, P Imhof, H Neubauer.   

Abstract

Cardiovascular effects of therapeutic doses of tricyclic or tetracyclic antidepressants (TCA) were examined in 66 patients. After three weeks of therapy, heart rate and PR interval were increased (P less than .02, P less than .05), while prolongation of the QTc time and the QRS interval did not reach significant levels. We observed significant flattening of T waves (P less than .05), which was not associated with changes in the serum potassium level. These changes were reversible after treatment was discontinued. When therapy was maintained for 13 months, only the heart rate continued to be increased, whereas all other ECG values had returned to normal. The TCA therapy led to a significant prolongation of the preejection period (P less than .01) and slight shortening of the left ventricular ejection time, indicating a decrease in myocardial contractility. There was no difference of effects on the values studied between tricyclic and tetracyclic antidepressants.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 579392

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  29 in total

Review 1.  Adverse effects of antidepressants in the elderly.

Authors:  L Nolan; K O'Malley
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

2.  Cardiovascular effects of paroxetine.

Authors:  H Kuhs; G A Rudolf
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.

Authors:  S J Warrington; P Turner; B K Skrumsager
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

4.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

6.  Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients.

Authors:  C D Burgess; S Montgomery; J Wadsworth; P Turner
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

Review 7.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

Review 8.  Chest pain and angiographically normal coronary arteries. Implications for treatment.

Authors:  V Mukerji; B D Beitman; M A Alpert
Journal:  Tex Heart Inst J       Date:  1993

9.  Mianserin, maprotiline and intracardiac conduction.

Authors:  J G Edwards; A Goldie
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

10.  Mianserin: cardiovascular effects in elderly patients.

Authors:  M Møller; P Thayssen; P Kragh-Sørensen; O L Pedersen; C B Kristensen; M Bjerre; S Benjaminsen; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.